2011 could be a great year but GSK might manage to push some of that expense into 2012. That would make 2012 a reasonable year and I guess royalies could be up to about $100M in each year. 2013 is expected to be a bumper royalty year as US replaces US$2.8 billion of expiring 2006 tamiflu stockpile with relenza (see Wikipedia). Again if GSK manages to spread some of that into 2014 the royalty could be about US$98M for each of those years.
Anyone care to do some calculations?
BTA Price at posting:
97.0¢ Sentiment: None Disclosure: Held
